AI's Dark Side Risks of Powerful New Tech Deniz Kent, co-founder and CEO of Prolific Machines, has raised over $90M from top investors for his biotech company. He discusses pivoting his company and the importance of raising capital when it is not critically needed to maximize leverage and terms. What this video coversIn the world of biotech, where cutting-edge research often remains locked within academic institutions, Deniz Kent, Ph.D., is defying convention. He is the co-founder and CEO of Prolific Machines, a company he created on the radical idea of controlling biology with light.Prolific Machines has secured capital from top-tier investors like Pledge Ventures, IndieBio, Ki Tua Fund, and Breakthrough Energy Ventures.Deniz Kent transitioned from academic research to entrepreneurship by founding Prolific Machines, driven by a desire to solve limitations in biological control tools.Prolific Machines uses optogenetics—controlling cells with light—to revolutionize biomanufacturing with higher precision and lower costs.Due to stronger economics and market demand, the company pivoted from growing cultured meat to manufacturing therapeutic proteins.Deniz has raised over $90M from top investors, including IndieBio, Mayfield, Breakthrough Energy Ventures, and Fonterra.He emphasizes raising capital when you don’t need it, to maximize leverage and terms.His immigrant background instilled resilience and a strong work ethic that shaped his entrepreneurial mindset.Deniz believes all biomanufacturing will become optogenetic due to light’s unmatched control and cost efficiency. More from the librarySelling Shovels StrategyLucky Timing How We Built Social Media in 2021The Future of Jobs Rewarding Creativity, Not RepetitionSeed Round Fundraising Second Time Founder's Unique Strategy 1Superblocks Revolutionary AI App Generation for EveryoneFrictionless Customer Interaction Watch on Startup Fundraising · Open on YouTube · More shorts
